Community-based thrombolytic therapy of acute ischemic stroke in Helsinki

Stroke

Volumn 34, Issue 6, 2003, Pages 1443-1449

  Lindsberg, Perttu J ^a   Soinne, Lauri ^a   Roine, Risto O ^a   Salonen, Oili ^a   Tatlisumak, Turgut ^a   Kallela, Mikko ^b   Häppölä, Olli ^a   Tiainen, Marjaana ^a   Haapaniemi, Elena ^b   Kuisma, Markku ^a   Kaste, Markku ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

Hemorrhage; Outcome; Stroke; Stroke, ischemic; Thrombolysis

Indexed keywords

ALTEPLASE; ANTIHYPERTENSIVE AGENT; GLYCERYL TRINITRATE; LABETALOL; METOPROLOL;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; BLOOD PRESSURE MONITORING; BRAIN HEMATOMA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEATH; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; HEMISPHERE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOPLASTIN TIME; TREATMENT OUTCOME;

ACADEMIC MEDICAL CENTERS; ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMMUNITY HEALTH CENTERS; DEMOGRAPHY; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; FINLAND; HUMANS; LABETALOL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECOVERY OF FUNCTION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0013216143     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000071111.98505.C7     Document Type: Article

References (20)

1. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
2. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
4. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
5. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke. 1996;27:1711-1718.
6. Wardlaw J, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev. 2000; (4).
7. Larrue V, von Kummer R, Müller A, Bluhmki. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438-441.
8. von Kummer R. Effect of training in reading CT scans on patient selection for ECASS II. Neurology. 1998;51(suppl 3):S50-S52.
9. Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:330-1335.
10. Hill MD, Buchan AM, for the CASES Investigators. CASES: final results. Can J Neurol Sci. 2002;29:534. (CCNS Meeting, Vancouver, British Columbia, June 2002.)
11. Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss W-D. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke. 1998;29:1544-1549.
12. Chapman KM, Woolfenden AR, Graeb D, Johnston DCC, Beckman J, Schultzer M, Teal PA. Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian hospital's experience. Stroke. 2000;31:2920-2924.
13. Merino JG, Silver B, Wong E, Foell B, Demaerschalk B, Tamayo A, Poncha F, Hachinski V. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke. 2002;33:141-146.
14. Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W, for the ECASS Study Group. The ECASS 3-hour cohort: secondary analysis of ECASS data by time stratification. Cerebrovasc Dis. 1998;8:198-203.
15. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Effect of blood pressure and diabetes on stroke in progression. Lancet. 1994;344:156-159.
16. Kaste M, Fogelholm R, Erilä T, Palomaki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke. 1994;25:1348-1353.
17. Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke. 2000;31:1250-1255.
18. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830-2838.
19. von Kummer R, Bourquain H, Bastianello S, Bozzao L, Manelfe C, Meier D, Hacke W. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology. 2001;219:95-100.
20. Lindsberg PJ, Kaste M. Thrombolysis for acute stroke. Curr Opin Neurol. 2003;16:73-80.